FDA proposes excluding Novo, Lilly GLP-1s from compounding list
The headquarters of the U.S. Food and Drug Administration in Silver Spring, Maryland, Nov. 4, 2009. Jason Reed | Reuters The Food and Drug Administration on Thursday proposed excluding the active ingredients in Novo Nordisk and Eli Lilly‘s blockbuster obesity and diabetes medications from the list of drugs that outsourcing facilities can use for compounding…
